Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 0.66%.

  • Foghorn Therapeutics' Return on Capital Employed fell 2600.0% to 0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66%, marking a year-over-year decrease of 2600.0%. This contributed to the annual value of 0.47% for FY2024, which is 1000.0% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Return on Capital Employed stood at 0.66%, which was down 2600.0% from 0.56% recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Return on Capital Employed high stood at 0.23% for Q1 2022, and its period low was 0.66% during Q3 2025.
  • Over the past 5 years, Foghorn Therapeutics' median Return on Capital Employed value was 0.42% (recorded in 2023), while the average stood at 0.41%.
  • Per our database at Business Quant, Foghorn Therapeutics' Return on Capital Employed surged by 2300bps in 2022 and then crashed by -2600bps in 2025.
  • Foghorn Therapeutics' Return on Capital Employed (Quarter) stood at 0.33% in 2021, then increased by 3bps to 0.32% in 2022, then tumbled by -39bps to 0.45% in 2023, then fell by 0bps to 0.45% in 2024, then plummeted by -48bps to 0.66% in 2025.
  • Its last three reported values are 0.66% in Q3 2025, 0.56% for Q2 2025, and 0.49% during Q1 2025.